Cardiovascular (CV) event risk assessment in psoriasis (Ps) patients treated with tumor necrosis factor-alpha inhibitors (TNFi) versus phototherapy - 21/04/16
Jashin Wu, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, United States; Martin Cloutier, Analysis Group, Inc, Boston, MA, United States; Marjolaine Gauthier-Loiselle, Analysis Group, Inc, Boston, MA, United States; Annie Guérin, Analysis Group, Inc, Boston, MA, United States; Murali Sundaram, AbbVie Inc, North Chicago, IL, United States
Le texte complet de cet article est disponible en PDF. Design, study conduct, and financial support for the study were provided by AbbVie; AbbVie participated in the interpretation of data, review, and approval of the abstract; all authors contributed to the development of the publication. |
Vol 74 - N° 5S1
P. AB238 - mai 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?